Courtney DiNardo, MD, MSCE

Articles

Future Horizons in the Treatment of Myelodysplastic Syndromes

February 7th 2025

Panelists discuss how the future treatment landscape for myelodysplastic syndromes (MDS) appears promising with several ongoing clinical trials exploring novel combinations and targeted therapies, including investigations of venetoclax combinations, magrolimab, sabatolimab, and other immune-based approaches that could potentially improve outcomes across different risk groups and molecular subtypes.

A Deep Dive Into Treatment Approaches for Patients With MDS by Risk Status

February 7th 2025

Panelists discuss how treatment strategies for myelodysplastic syndromes (MDS) are fundamentally guided by risk stratification, with lower-risk patients typically receiving supportive care and less intensive treatments focused on quality of life and symptom management while intermediate- to high-risk patients require more aggressive approaches, including hypomethylating agents and consideration for stem cell transplantation, with emerging data supporting novel combinations and targeted therapies across the risk spectrum.

Clinical Insights: Key Data Presented at ASH 2024 in MDS

January 31st 2025

Panelists discuss how oral decitabine/cedazuridine demonstrated meaningful clinical activity in patients with TP53-mutated myelodysplastic syndromes (MDS), with a 31% complete response rate and 16.1-month median overall survival, representing an important treatment advance for this traditionally poor-prognosis molecular subgroup.

Comparison of Oral vs Intravenous Hypomethylating Agents in the Treatment of MDS

January 31st 2025

Panelists discuss how oral decitabine/cedazuridine showed encouraging efficacy in patients with myelodysplastic syndromes (MDS) with TP53 mutations, suggesting this oral formulation could be particularly beneficial for this historically difficult-to-treat molecular subgroup.

ASCERTAIN Trial: Key Data of Oral Decitabine and Cedazuridine in MDS

January 24th 2025

Panelists discuss how the ASCERTAIN trial demonstrated that oral decitabine plus cedazuridine provided comparable efficacy to injectable decitabine.

Introducing Hypomethylating Agents for Patients With MDS

January 24th 2025

Panelists discuss how hypomethylating agents remain the cornerstone of therapy for intermediate to high-risk patients with myelodysplastic syndromes (MDS).

MDS Treatment Strategies: From Risk Assessment to Transplantation

January 17th 2025

Panelists discuss how the primary therapeutic goals for patients with intermediate- to high-risk myelodysplastic syndromes (MDS) focus on extending survival and modifying disease course through intensive treatments like hypomethylating agents or stem cell transplantation while addressing unique challenges such as treatment resistance, poor response durability, and limited options after hypomethylating agents failure.

Evolving Horizons: MDS Diagnosis and Risk Stratification in 2024

December 20th 2024

The panelists discuss the newest risk stratification tool, IPSS-M.

Dr DiNardo on the FDA Approval of Ivosidenib in Relapsed/Refractory, IDH1+ MDS

October 24th 2023

Courtney D. DiNardo, MD, MSCE, discusses the significance of the FDA approval of ivosidenib in patients with relapsed/refractory, IDH1-mutated myelodysplastic syndromes.

​​Dr DiNardo on Alternative Triplet Regimens For Select Patients With AML

September 14th 2023

Courtney DiNardo, MD, MSCE, discusses triplets that serve as alternatives to standard-of-care approaches with azacitidine and venetoclax doublet therapy in select patients with acute myeloid leukemia.

Women in Oncology: Leaving Passionate Legacies

October 28th 2022

Courtney DiNardo, MD, MSCE; Eunice Wang, MD; and Jessica Altman, MD, discuss the scientific achievements they have witnessed in the field of leukemia and their hopes for the future of treating this disease.

Women in Oncology: The Value of Female Leadership

October 28th 2022

Courtney DiNardo, MD, MSCE; Eunice Wang, MD; and Jessica Altman, MD, discuss how they turned career obstacles into opportunities and what they have learned from being women in the leukemia field.

Women in Oncology: Opportunities for Success Through Mentorship

October 27th 2022

Courtney DiNardo, MD, MSCE; Eunice Wang, MD; and Jessica Altman, MD, discuss the importance of strong mentorship relationships and the unique growth opportunities they found at different points of their careers.

Women in Oncology: Actively Preparing for Advances in Leukemia Treatment

October 27th 2022

Courtney DiNardo, MD, MSCE; Eunice Wang, MD; and Jessica Altman, MD, discuss the toughest challenges they faced in the leukemia field at the start of their fellowships and careers.

Dr. DiNardo on the FDA Approval of Oral Azacitidine in AML

September 1st 2020

Courtney DiNardo, MD, MSCE, discusses the FDA approval of oral azacitidine (CC-486) in acute myeloid leukemia (AML).

Dr. DiNardo on the Rationale for the Pooled Analysis Evaluating Venetoclax in AML

June 26th 2020

Courtney DiNardo, MD, MSCE, discusses the rational​e for a pooled analysis evaluating venetoclax in acute myeloid leukemia.

Dr. DiNardo on the Results of the VIALE-A Trial in AML

June 13th 2020

Courtney DiNardo, MD, MSCE, discusses the results of the phase 3 VIALE-A trial in acute myeloid leukemia (AML).

Dr. DiNardo on Timing and Impact of Response to Venetoclax Combinations in AML

June 11th 2020

Courtney DiNardo, MD, MSCE, iscusses findings from a pooled analysis examining venetoclax (Venclexta) combination treatment in acute myeloid leukemia.

Dr. DiNardo on Timing and Impact of Response to Venetoclax Combinations in AML

June 10th 2020

Courtney DiNardo, MD, MSCE, discusses findings from a pooled analysis examining venetoclax (Venclexta) combination treatment in acute myeloid leukemia.

Dr. DiNardo on the Role of Venetoclax in AML

June 3rd 2020

Courtney DiNardo, MD, MSCE, discusses the role of venetoclax (Venclexta) in acute myeloid leukemia (AML).

NEXT PAGE
PREVIOUS PAGE